Inherited Arrhythmias – Where do we Stand?

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare:

For permissions and non-commercial reprint enquiries, please visit to start a request.

For author reprints, please email
Average (ratings)
No ratings
Your rating


This review discusses inherited arrhythmias and conduction disturbances due to genetic disorders. Known channel mutations that are responsible for these conditions are presented, the indications and value of genetic testing are discussed, and a glossary of terms related to the discipline of genetic cardiology has been compiled.

Disclosure:The authors have no conflicts of interest to declare.



Correspondence Details:D Katritsis, Athens Euroclinic, 9 Athanassiadou St, Athens 11521, Greece. E:,

Copyright Statement:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

Inherited arrhythmias comprise a group of disorders with inherited susceptibility to arrhythmias and conduction disturbances due to mutations in genes mainly encoding the Na+, and K+ channels, and other arrhythmogenic mechanisms such as those linked to Ca++ transport (Table 1).1 The majority of heritable cardiomyopathies and channelopathies are associated with disease-susceptibility genes characterised by incomplete penetrance, ie low likelihood that the mutation will cause clinically recognisable disease. Thus, although these disease entities are monogenic, there is variable penetrance, which reflects contribution by modifier genes, thus resulting in diverse phenotypes.2 Usually they are familial, rather than sporadic, and autosomal dominant rather than autosomal recessive.

Genetic testing has now emerged as a useful clinical tool for the diagnosis and risk stratification of genetic conditions but distinguishing pathological mutations from innocent genetic variants is not always straightforward. Currently, genetic testing may put the diagnosis in long QT syndrome (LQTS), catecholaminergic polymorphic ventricular tachycardia (CPVT), Brugada syndrome (BrS) and hypertrophic obstructive cardiomyopathy (HOCM), and may also facilitate risk stratification in LQTS and HOCM.3 According to the 2010 consensus statement of HRS/EHRA, genetic testing is recommended in cases with a sound clinical suspicion for the presence of a channelopathy or a cardiomyopathy when the positive predictive value of a genetic test is high (likelihood of positive result >40 % and signal/noise ratio <10) (Table 2).4

The conventional approach of genetic linkage analysis has been replaced with the newer approach of genome-wide association studies (GWAS), and high-throughput, next-generation DNA sequencing (NGS).5 The application of high-throughput techniques for whole genome and exome sequencing are exciting future advancements of this technology,6–8 although questions remain about its clinical applicability and cost-effectiveness.9 In November 2013, the FDA approved marketing of four diagnostic devices that can be used for high-throughput gene sequencing.

The DNA of humans consists of the same nucleotide sequence, but normal variations in small sections of sequence or single nucleotides do exist among individuals (polymorphisms). Single nucleotide substitutions that occur with a measurable frequency (ie >0.5 % allelic frequency) among a particular ethnic population are called singlenucleotide polymorphisms, whereas those that occur less frequently are termed mutations.

Glossary of Terms
Allele: One of several alternative versions of a particular gene. An allele can refer to a segment of DNA or even a single nucleotide. The normal version of genetic information is often considered the ‘wild-type’ or ‘normal’ allele. The vast majority of the human genome represents a single version of genetic information. One phenotype may be controlled by multiple alleles, but only a combination of two will determine the phenotype. For example, the blood group gene has three alleles – A, B and O – but people only have a twoallele phenotype.

Autosomal Dominant: The situation in which the disease can be expressed even when just one chromosome harbours the mutation.

Autosomal Recessive: The situation in which the disease is expressed only when both chromosomes of a pair are abnormal.

Cascade Testing: Procedure whereby all first-degree relatives of a genotype-positive index case are tested in concentric circles of relatedness. If one of the family members is genotype positive, all his/ her first-degree relatives should be tested, continuing this process for each genotype-positive family member.
Known channel mutations in genetic channelopathies.
Download original

Known channel mutations in genetic channelopathies (Continued)
Download original
Yield and Signal-to-Noise Associated with Disease-Specific Genetic Testing
Download original
Compound heterozygosity: more than one genetic defect in the same gene.

Digenic heterozygosity: more than one genetic defect in a second complementary gene.

Epigenetics: Mitotically and/or meiotically heritable variations of gene function that cannot be explained by changes of DNA sequence. Exome: The subset of the human genome that encodes proteins (1–2 % of the total genome); it encompasses approximately 19,000 genes.

Expressivity: The level of expression of the phenotype.When the manifestations of the phenotype in individuals who have the same genotype are diverse, the phenotype is said to exhibit variable expressivity.

Genotype: A person’s genetic or DNA sequence composition at a particular location in the genome.

Genotypic heterogeneity: Genetic variability among individuals with similar phenotypes.

Genotype–phenotype plasticity: The concept that the link between genotype and phenotype is subject to broad variability with as yet limited predictability.

Genome-wide association studies: Examination of many common genetic variants in individuals with and without a disease trait, to identify a possible higher frequency (ie association) of singlenucleotide polymorphisms in people with the trait.

Haploinsufficiency: The situation in which an individual who is heterozygous for a certain gene mutation or hemizygous at a particular locus, often due to a deletion of the corresponding allele, is clinically affected because a single copy of the normal gene is incapable of providing sufficient protein production for normal function. This is an example of incomplete or partial dominance.

Heterozygote: An individual who has different alleles at a particular gene locus on homologous chromosomes (carrier of a single copy of the mutation).

Homozygote: An individual who has the same allele at a particular gene locus on homologous chromosomes (carrier of a double copy of the mutation).

Matrilinear inheritance: Women but not men transmit the disease to offspring (male or female), as happens with disease due to mitochondrial DNA mutations.

Modifier: Gene variants or environmental factors that are insufficient to cause observable disease on their own, but which are capable of interacting with the disease gene to alter the phenotype.

Mutation: A change of the DNA sequence within the genome. A mutation considered in the context of a genetic disease usually refers to an alteration that causes a Mendelian disease, whereas a genetic polymorphism refers to a common genetic variation observed in the general population.

Mutation – Deletion/Insertion: The removal (deletion) or addition (insertion) of nucleotides to the transcript that can be as small as a single nucleotide insertion/deletion or as large as several hundreds to thousands of nucleotides in length.

Mutation – Disease Causing: A DNA sequence variation that represents an abnormal allele and is not found in the normal healthy population but exists only in the disease population and produces a functionally abnormal product.

Mutation – Frameshift: Insertions or deletions occurring in the exon that alter the ‘reading frame’ of translation at the point of the insertion or deletion and produce a new sequence of amino acids in the finished product. Frameshift mutations often result in a different product length from the normal gene product by creating a new stop codon, which produces either a shorter or longer gene product depending on the location of the new stop codon.

Mutation – Germline: Heritable change in the genetic make-up of a germ cell (sperm or ovum) that when transmitted to an offspring is incorporated into every cell in the body.

Mutation – In-Frame Insertion/Deletion: In-frame insertions and deletions occur when a multiple of three nucleotides is affected and result in single or multiple amino acids being removed or added without affecting the remainder of the transcript.

Mutation – Missense: A single nucleotide substitution that results in the exchange of a normal amino acid in the protein for a different amino acid.

Mutation – Nonsense: A single nucleotide substitution resulting in a substitution of an amino acid for a stop codon. A nonsense mutation results in a truncated (shortened) gene product at the location of the new stop codon.

Mutation – Somatic: Variants/mutations are said to be somatic if they occur in cells other than gametes. Somatic mutations cannot be transmitted to offspring.

Penetrance: The likelihood that a gene mutation will have any expression at all. In the situation in which the frequency of phenotypic expression is less than 100%, the genetic defect is said to be associated with reduced or incomplete penetrance.

Phenocopy: An individual who manifests the same phenotype (trait) as other individuals of a particular genotype but does not possess this genotype himself/herself.

Phenotype: A person’s observed clinical expression of disease in terms of a morphological, biochemical or molecular trait.

Phenotypic heterogeneity: Phenotypic variability among individuals with similar genotypes.

Polymorphism: Normal variations at distinct loci in the DNA sequence. The vast majority of the human genome represents a single version of genetic information. The DNA from one person is mostly made up of the same nucleotide sequence as another person. However, there are many small sections of sequence or even single nucleotides that differ from one individual to another.

Proband or index case or propositus: The first affected family member who seeks medical attention for a genetic disease.

Single Nucleotide Polymorphism (SNP): A single nucleotide substitution that occurs with a measurable frequency (i.e. >0.5 % allelic frequency) among a particular ethnic population(s).

SNP – Nonsynonymous: A single nucleotide substitution whereby the altered codon encodes for a different amino acid or terminates further protein assembly, i.e. introduces a premature stop codon.

SNP – Synonymous: A single nucleotide substitution occurring in the coding region (exon), whereby the new codon still specifies the same amino acid.

X-linked inheritance: a recessive mode of inheritance in which a mutation in a gene on the X chromosome causes the phenotype to be expressed in males (who are necessarily hemizygous for the gene mutation) and in females who are homozygous for the gene mutation.


  1. Leenhardt A, Denjoy I, Guicheney P. Catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol. 2012;5:1044–52.
    Crossref | PubMed
  2. Golbus JR, Puckelwartz MJ, Fahrenbach JP, et al. Populationbased variation in cardiomyopathy genes. Circ Cardiovasc Genet. 2012;5:391–9.
    Crossref | PubMed
  3. Tester DJ, Ackerman MJ. Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelopathies in clinical practice. Circulation. 2011;123:1021–37.
    Crossref | PubMed
  4. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies: This document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). Europace 2011;13:1077–109.
    Crossref | PubMed
  5. Roberts R, Marian AJ, Dandona S, Stewart AF. Genomics in cardiovascular disease. J Am Coll Cardiol 2013;61:2029–37.
    Crossref | PubMed
  6. Dewey FE, Pan S, Wheeler MT, et al. DNA sequencing: Clinical applications of new DNA sequencing technologies. Circulation 2012;125:931–44.
    Crossref | PubMed
  7. Schwartz P, Ackerman MJ, George AL, et al. Impact of genetics on the clinical management of channelopathies. J Am Coll Cardiol 2013;62:169–80.
    Crossref | PubMed
  8. Ganesh SK AD, Assimes TL, Basson CT, et al; on behalf of the AHA Council on Functional Genomics and Translational Biology; AHA Council on Epidemiology and Prevention; AHA Council on Basic Cardiovascular Sciences; AHA Council on Cardiovascular Disease in the Young; AHA Council on Cardiovascular and Stroke Nursing; AHA Stroke Council. Genetics and genomics for the prevention and treatment of cardiovascular disease: Update: A scientific statement from the American Heart Association. Circulation 2013;128:2813–51.
  9. Dewey FE GM, Pan C, Goldstein BA, et al. Clinical interpretation and implications of whole-genome sequencing. JAMA 2014;311:1035–45.
    Crossref | PubMed